Johan Vansteenkiste
About
In The Last Decade
Johan Vansteenkiste
215 papers receiving 9.8k citations
Hit Papers
Peers
Comparison fields: 5 of 134
- Pulmonary and Respiratory Medicine 6.9k
- Oncology 3.2k
- Radiology, Nuclear Medicine and Imaging 3.1k
- Molecular Biology 1.3k
- Surgery 812
Countries citing papers authored by Johan Vansteenkiste
This map shows the geographic impact of Johan Vansteenkiste's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Johan Vansteenkiste with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Johan Vansteenkiste more than expected).
Fields of papers citing papers by Johan Vansteenkiste
This network shows the impact of papers produced by Johan Vansteenkiste. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Johan Vansteenkiste. The network helps show where Johan Vansteenkiste may publish in the future.
Co-authorship network of co-authors of Johan Vansteenkiste
This figure shows the co-authorship network connecting the top 25 collaborators of Johan Vansteenkiste. A scholar is included among the top collaborators of Johan Vansteenkiste based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Johan Vansteenkiste. Johan Vansteenkiste is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 15 | |
| 2 | 12 | |
| 3 | 0 | |
| 4 | 59 | |
| 5 | 51 | |
| 6 | Transcriptome Sequencing of Tumor vs. Surrounding Non-Malignant Lung Tissue in Non-Small Cell Lung Cancer | 1 |
| 7 | 257 | |
| 8 | IMPACT OF GERIATRIC ASSESSMENT ON TREATMENT DECISIONS IN OLDER LUNG CANCER PATIENTS | 2 |
| 9 | MODERN POST-OPERATIVE RADIOTHERAPY FOR STAGE III NON-SMALL CELL LUNG CANCER MAY IMPROVE LOCAL CONTROL AND SURVIVAL: A PUBLICATION-BASED META-ANALYSIS | 1 |
| 10 | MAINTENANCE THERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER: HOW DOES MY PATIENT FEEL ABOUT IT? | 1 |
| 11 | HEALTH-RELATED QUALITY OF LIFE IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS | 1 |
| 12 | 197 | |
| 13 | 4 | |
| 14 | A randomized, parallel-group, phase II study to evaluate the efficacy and safety of three doses of the integrin inhibitor cilengitide compared with docetaxel in patients with stage IV non-small cell lung cancer (NSCLC) after failure of first-line chemotherapy | 1 |
| 15 | Pemetrexed is more effective in patients with nonsquamous non-small cell lung cancer (NSCLC) histology: an analysis of three large, randomized, phase III trials | 3 |
| 16 | 44 | |
| 17 | Reflections on the current staging system for lung cancer | 1 |
| 18 | Role of 18F-2-deoxyglucose positron emission tomography (FDG-PET) after induction chemotherapy In stage IIIA-N2 non-small cell lung cancer (N2-NSCLC) | 3 |
| 19 | Lymph node mapping in non-small cell lung cancer with FDG-PET scan: a prospective study in 690 LN levels from 68 patients | 3 |
| 20 | Bronchuscarcinoom in Vlaanderen. | 1 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.